TFA Therapeutics (RAJAF) Accumulated Expenses (2020 - 2025)

TFA Therapeutics has reported Accumulated Expenses for 6 years, with the latest figure at $85074.0 in Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 162.49% year-over-year to $85074.0 in Q4 2025; TTM through Dec 2025 was $85074.0, a 162.49% increase from a year earlier, with the FY2025 full-year figure at $85074.0, up 162.49% from the prior year.
• Accumulated Expenses was $85074.0 for Q4 2025 at TFA Therapeutics, up from $32410.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $85074.0 in Q4 2025, with the low at $26889.0 in Q4 2023.
• Average Accumulated Expenses over 5 years is $52706.8, with a median of $56407.0 recorded in 2021.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses slumped 57.15% in 2023, then surged 162.49% in 2025.
• Over 5 years, Accumulated Expenses stood at $56407.0 in 2021, then increased by 11.25% to $62754.0 in 2022, then plunged by 57.15% to $26889.0 in 2023, then rose by 20.53% to $32410.0 in 2024, then soared by 162.49% to $85074.0 in 2025.
• The last three Accumulated Expenses figures came in at $85074.0 (Q4 2025), $32410.0 (Q4 2024), and $26889.0 (Q4 2023), per Business Quant data.